Bellerophon Therapeutics, Inc.
BLPHDelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001600132
Bellerophon Therapeutics, Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Oct 16, 2023; 22 institutions reported holding it in 13F filings for Q3 2023, worth $506.6K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 22
- Q3 2023, −1 vs. previous quarter
- 13F value
- $506.6K
- Reported value at the end of Q3 2023
- Superinvestors holding
- 0
- At the end of Q3 2023
Superinvestors holding BLPH, Q3 2023
No superinvestor reported holding BLPH at the end of Q3 2023.
Latest insider trades
Open-market purchases and sales by Bellerophon Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2023 (view filing)8:51 PM ET | Oct 13 | 3 days | Puissance Capital Management LP and 3 others10% Owner | SSale | −1.08M | $0.1038 | −$111.8K | −100.0%0 after | |
| Jun 7, 2023 (view filing)9:21 PM ET | Jun 7 | Same day | Wang Theodore T and 3 othersDirector, 10% Owner | SSale | −134.4K | $0.83 | −$111.6K | −11.1%1.08M after | |
| May 22, 2023 (view filing) | May 18 | 4 days | Kim BobaeVP Reg. Affairs & Quality | SSale | −9.46K | $10.00 | −$94.5K | −84.6%1.72K after | |
| May 19, 2023 (view filing)8:55 PM ET | May 18 | 1 day | Wang Theodore T and 3 othersDirector, 10% Owner | SSale | −560.0K | $9.46 | −$5.30M | −31.6%1.21M after |
Top 10 13F holders, Q3 2023
The largest institutional positions in Bellerophon Therapeutics, Inc. at the end of Q3 2023; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Acadian Asset Management LLC | 383,178 | $152.0K | 0.00% | +117,925+44.5% | Added |
| Wells Fargo & Company | 180,066 | $71.6K | 0.00% | −20,009−10.0% | Reduced |
| Vanguard Group Inc | 145,810 | $58.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 127,723 | $50.8K | 0.00% | −2,153−1.7% | Reduced |
| Two Sigma Investments, LP | 113,911 | $45.3K | 0.00% | +10,124+9.8% | Added |
| Geode Capital Management, LLC | 95,656 | $38.3K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 59,499 | $24.0K | 0.00% | −17,800−23.0% | Reduced |
| Citadel Advisors LLC | 42,717 | $17.1K | 0.00% | +42,717 | New |
| State Street Corp | 30,127 | $12.1K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 30,251 | $12.0K | 0.00% | −7,970−20.9% | Reduced |
Holders of 5% or more of BLPH
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Bellerophon Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Nelson Michael Aaron | 13G | 5.30%642.8K shares | 0.00 ppfrom 5.30% | Jan 26, 20242 filings | Mar 1, 2024 | SEC |